CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Inclusion Criteria:

• Patients must have measurable disease.

• Age ≥ 12 years (Phase 2)

• Adequate renal function

• Adequate liver function

• Adequate hematological function

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Life expectancy of at least three months.

Exclusion Criteria:

• Patients must not have clinically significant cardiac disease.

• Patients must not have known non-controlled CNS metastasis.

• Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy aswell as known or suspected allergy or intolerance to any agent given during thisstudy.

• Patients must not have had major surgery within 4 weeks before first BA3011administration.

• Patients must not have had prior therapy with a conjugated or unconjugatedauristatin derivative/vinca-binding site targeting payload.

• Patients must not have known human immunodeficiency virus (HIV) infection, activehepatitis B and/or hepatitis C.

• Patients must not be women who are pregnant or breast feeding.